Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETER701: Benmelstobart and Anlotinib in Extensive Stage Small Cell Lung Cancer
NCT04234607Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benmelstobart and anlotinib in small cell lung cancer (SCLC) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Progression-Free Survival up to 12 months and Overall Survival up to 24 months. Status: unknown.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04234607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234607.